Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Zepatier (elbasvir and grazoprevir by Quarter
Zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%)
Merck Zepatier (elbasvir and grazoprevir: -76.0% in Q3 2020, down 106.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the Q3 2020 figure comes from
“|| Zepatier | 28 | 83 | -67 | 6 | 24 | -76 | 22 | 59 | -63”
Source: Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2020 | Sep 30, 2020 | -76.0% | -106.0 pts | Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | -62.0% | – | Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | -46.0% | – | Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗ |
| Q3 2019 | Sep 30, 2019 | 30.0% | +122.0 pts | Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗ |
| Q3 2018 | Sep 30, 2018 | -92.0% | – | Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | -104.0% | – | Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗ |
| Q4 2017 | Dec 31, 2017 | -51.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Zepatier (elbasvir and grazoprevir (%), quarterly Q4 2017–Q3 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zepatier-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.